Drugs in Dev. Infections and Infectious Diseases
IND Enabling
Australia 
Lead Product(s) : INNA-051
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ENA Respiratory Receives FDA IND Clearance for Intranasal INNA-051
Details : INNA-051 is a TLR2/6 agonist, small molecule drug candidate in development as an innate immune modulator, delivered using a nasal spray. It is being evaluated for the treatment of Influenza.
Product Name : INNA-051
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2024
Lead Product(s) : INNA-051
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CampETEC
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Naval Medical Research Center (NMRC) has executed a research agreement with Immuron to develop and clinically evaluate a new therapeutic CampETEC, targeting Campylobacter and ETEC infections.
Product Name : CampETEC
Product Type : Vaccine
Upfront Cash : Inapplicable
January 25, 2023
Lead Product(s) : CampETEC
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immuron Receives FDA Approval for Travelan IND Application
Details : The Investigational New Drug (IND) application to evaluate the efficacy of a single dose of Travelan (bovine colostrum) to prevent infectious diarrhea caused by ETEC is now active.
Product Name : Travelan
Product Type : Antibody
Upfront Cash : Inapplicable
December 23, 2022
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : US Naval Medical Research Command
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The NMRC received written guidance from FDA in relation to clinical development pathway of the new drug which the company is developing to treat moderate to severe campylobacteriosis and Enterotoxigenic Escherichia coli (ETEC) infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 26, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : US Naval Medical Research Command
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Immuron Submits IND Application To FDA for Travelan
Details : Travelan (bovine colostrum) is an over the counter immune supplement that can be taken to reduce the risk of diarrhoea and reduce the symptoms of minor gastrointestinal disorders. Travelan® helps to support a healthy digestive system by supporting the g...
Product Name : Travelan
Product Type : Antibody
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Pharmaron
Deal Size : Undisclosed
Deal Type : Agreement
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
Details : The Phase II clinical trial will evaluate the efficacy of a single dose regimen of Travelan® in a controlled human infection model (CHIM) using the enterotoxigenic Escherichia coli (ETEC) strain H10407.
Product Name : Travelan
Product Type : Antibody
Upfront Cash : Undisclosed
April 10, 2022
Lead Product(s) : Bovine Colostrum
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Pharmaron
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : INNA-051
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The self-administered nasal spray, INNA-051, is being developed to stimulate the innate immunity in the nose, where most respiratory viral infections begin. INNA-051 is a potent innate immune agonist that targets the receptor TLR2/6.
Product Name : INNA-051
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : INNA-051
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RECCE® 327 Demonstrates Outstanding Efficacy Against Necrotizing Fasciitis
Details : The study was conducted by an independent contract research organization to evaluate the in vitro bactericidal properties of R327 against C. perfringens and S. pyogenes.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 20, 2021
Lead Product(s) : R327
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : INNA-051
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Brandon Capital
Deal Size : $24.0 million
Deal Type : Financing
ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round
Details : The new financing will advance INNA-051, ENA Respiratory’s lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.
Product Name : INNA-051
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 15, 2021
Lead Product(s) : INNA-051
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Brandon Capital
Deal Size : $24.0 million
Deal Type : Financing
Reset All
